SAB Capra Awarded $225K from NIH to Broaden Novel Immunotherapy Platform – Business Wire (press release)
|
SAB Capra Awarded $225K from NIH to Broaden Novel Immunotherapy Platform
Business Wire (press release) SAB Capra, LLC is a privately-held, emerging bioscience company leveraging transgenic goats for the production of human polyclonal antibodies for use in diagnostics and testing, targeted immunotherapies and personalized medicine applications … |
